Viages de Enrique Wanton a las tierras incógnitas australes y al País de las Monas...

Wanton, Enrico es pseudónimo del Conde Zacaris de Seriman (Palau XXVIII, p. 52)Vaca de Guzman y Manrique, Gutierre Joaquin firma como Joaquín de Guzman y Manrique (Palau VI, p. 501)Sign.: [parágrafo]4, [paragrafo]4, A-Y4Las. hh. de lam. calc.:" J. Patiño, sculp.

Suplemento, o sea tomo tercero de los viages de Enrique Wanton al pais de las monas ...

Se trata de la primera parte del suplementoEnrico Wanton es seud. del Conde Zaccaria SerimanSign.: [calderón]-2[calderón]4, 3[calderón]2, A-Z4, 2A-2I4Notas a pie de págReclamosLas h. de grab. calc. "Patiño f.", entre p. 58-59 y p. 200-20

A Comprehensive Phenotypic and Functional Immune Analysis Unravels Circulating Anti-Phospholipase A2 Receptor Antibody Secreting Cells in Membranous Nephropathy Patients

Introduction: Primary membranous nephropathy (MN) is characterized by the presence of antipodocyte antibodies, but studies describing phenotypic and functional abnormalities in circulating lymphocytes are limited. Methods: We analyzed 68 different B- and T-cell subsets using flow cytometry in 30 MN patients (before initiating immunosuppression) compared with 31 patients with non-immune-mediated chronic kidney disease (CKD) and 12 healthy individuals. We also measured 19 serum cytokines in MN patients and in healthy controls. Lastly, we quantified the ex vivo production of phospholipase A2 receptor (PLA2R)-specific IgG by plasmablasts (measuring antibodies in culture supernatants and by the newly developed FluoroSpot assay [AutoImmun Diagnostika, Strasberg, Germany]) and assessed the circulating antibody repertoire by phage immunoprecipitation sequencing (PhIP-Seq). Results: After adjusting for multiple testing, plasma cells and regulatory B cells (BREG) were significantly higher (P < 0.05) in MN patients compared with both control groups. The percentages of circulating plasma cells correlated with serum anti-PLA2R antibody levels (P = 0.042) and were associated with disease activity. Ex vivo-expanded PLA2R-specific IgG-producing plasmablasts generated from circulating PLA2R-specific memory B cells (mBCs) correlated with serum anti-PLA2R IgG antibodies (P < 0.001) in MN patients. Tumor necrosis factor-alpha (TNF-alpha) was the only significantly increased cytokine in MN patients (P < 0.05), whereas there was no significant difference across study groups in the autoantibody and antiviral antibody repertoire. Conclusion: This extensive phenotypic and functional immune characterization shows that autoreactive plasma cells are present in the circulation of MN patients, providing a new therapeutic target and a candidate biomarker of disease activity

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Construyendo identidad: cooperación japonesa mediante la JICA (Agencia de Cooperación Internacional del Japón) en Myanmar y Tailandia (2007 – 2013)

En el caso del Estado japonés, la Agencia de Cooperación Internacional del Japón (JICA), es una herramienta de política exterior que contribuye a la construcción de una identidad benefactora. Lo anterior va de la mano con la idea de que para el constructivismo de Alexander Wendt, los Estados crean y afianzan sus identidades en circunstancias dadas socialmente. El presente estudio de caso expone los diferentes programas impulsados, gestionados y ejecutados por la JICA en Myanmar y Tailandia entre 2007 y 2013. Así pues, se analizan cómo el conjunto de acciones japonesas en ambos Estados del Sudeste Asiático coadyuvan a cimentar la imagen de un Japón benefactor en la región. Concluyendo que el Estado Nipón asiste por igual a Estados con coyunturas internas discrepantes, tanto a éstos con necesidades inmediatas por suplir, como aquellos con realidades semejantes a Japón.The Japan International Cooperation Agency (JICA) is a Japanese asset in terms of foreign affairs, due to the fact that it aids in the construction of a new benevolent identity for Japan. Moreover, in Alexander Wendt’s constructivism, States create and consolidate their identities through social circumstances. The following case study presents the different programs carried out by JICA in Myanmar and Thailand between 2007 and 2013. Making an analysis of how the Japanese actions help create the image of a benevolent Japan in Southeast Asia. Finally, concluding that Japan assists equally those States in need, and those whose reality resembles that of Japan

Viages de Enrique Wanton a las tierras incognitas australes, y al pais de las Monas : en donde se expresan las costumbres, caracter, ciencias, y policia de estos extraordinarios habitantes

This item features in the Monash University Library exhibition Tall Tales and True: Journeys Real and Imagined. View the virtual exhibitionBy Zaccaria Seriman, translated into Spanish and continued by G.J. Vaca de Guzma?n y Manrique. Not translated from English into Italian. Cf. Palau y Dulcet. Vol. 3 has title: Suplemento, o sea tomo tercero de los viages de Enrique Wanton ... ; v. 4 has title: Suplemento, o sea tomo quarto, y ultimo de los viages de Enrique Wanton ... Vol. 1: xvi, 175, [1] p., [7] leaves of plates; v. 2: [8], 223, [1] p., [2] leaves of plates; v. 3: xix, [1], 254, [2] p., [2] leaves of plates; v. 4: [4], 183, [1], ix, [3] p., [2] leaves of plates. Vol. 4 lacks plates between pp. 120-121 and pp. 146-147

Viages de Enrique Wanton a las tierras incognitas australes y al país de las monas ...

Wanton, Enrico es pseudónimo del Conde Zacaris de Seriman (Palau XXVIII, p. 52)Vaca de Guzmán y Manrique, Gutierre Joaquín firma como Joaquín de Guzman y Manrique (Palau VI, p. 501

Effects of salinity on the CO2 permeation across lipid bilayer for microalgae biofixation: A molecular dynamics study

The continuous threat of increasing CO2 concentration in the atmosphere has altered the carbon balance of our planet causing global climate change. Biological fixation of atmospheric CO2 by unicellular microorganisms such as microalgae is a promising technology pursued extensively by researchers as a means for carbon capture. The study aimed to provide an atomic level of study that will demonstrate the effect of the salinity on the mechanism of CO2 absorption across microalgae lipid bilayer. Molecular dynamics simulations were utilized to calculate the free energies of CO2 molecule as it permeates inside the microalgae cell. In thermodynamics, the transport process of a molecule can be demonstrated through its free energy gradient. Thus, calculating the free energies of CO2 molecule across microalgae lipid bilayer can elucidate the mechanisms of permeation processes. Four microalgae lipid bilayer structures were constructed that contains 128-DPPC (dipalmitoylphosphatidylcholine) lipid bilayer with 3640 water molecules with different NaCl concentrations: 0, 3, 13, and 19 NaCl molecules which correspond to a salinity level of 0, 50, 200, and 300 mM, respectively. The cavity insertion Widom method was used to calculate the free energy of CO2 molecule along the lipid bilayer. The results demonstrated that the salinity does not affect the free energies significantly, thus, it does not hamper CO2 transport across microalgae lipid membrane. © 2017, Springer Science+Business Media Dordrecht

Immune abnormalities in IgA nephropathy

Immunoglobulin A (IgA) nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and it is characterized by mesangial IgA deposition. Asymptomatic hematuria with various degrees of proteinuria is the most common clinical presentation and up to 20%-40% of patients develop end-stage kidney disease within 20 years after disease onset. The pathogenesis of IgAN involves four sequential processes known as the "four-hit hypothesis" which starts with the production of a galactose-deficient IgA1 (gd-IgA1), followed by the formation of anti-gd-IgA1 IgG or IgA1 autoantibodies and immune complexes that ultimately deposit in the glomerular mesangium, leading to inflammation and injury. Although several key questions about the production of gd-IgA1 and the formation of anti-gd-IgA1 antibodies remain unanswered, a growing body of evidence is shedding light on the innate and adaptive immune mechanisms involved in this complex pathogenic process. Herein, we will focus on these mechanisms that, along with genetic and environmental factors, are thought to play a key role in disease pathogenesis.Lay Summary Immunoglobulin A (IgA) nephropathy (IgAN) is a kidney disease caused by the deposition of antibodies (IgA) in the glomerulus, the filtering portion of the kidney. As a result, filtering properties of the kidneys are lost and larger molecules like proteins cross from the blood into the urine. Up to 20%-40% of patients develop end-stage kidney disease (requiring dialysis or transplant) within 20 years after disease onset. New treatment options have become available over the last few years. This paper reviews the IgAN immune abnormalities that are targeted by the new therapies